BioPharmSignal logoBioPharmSignal

Biotech News

Compass Therapeutics to Participate in Upcoming November Investor Events

Compass Therapeutics (CMPX)Compass TherapeuticsEarnings

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November/this quarter.

Related news

FATEFate Therapeutics2026-10-01 11:00 EST

Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

KURAKura Oncology2026-11-03 11:58 EST

Kura Oncology to Report Third Quarter Financial Results on November 10

URGNUroGen Pharma2026-10-27 22:00 EST

UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026

LEGNLegend Biotech Corporation2026-10-27 12:00 EST

Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

View all latest news

Compass Therapeutics

Antibody-Based Oncology Compass Therapeutics develops antibody therapies at the intersection of angiogenesis, tumor immunity and immune suppression. Its portfolio includes bispecific antibodies and immune activators intended to disrupt tumor blood supply while restoring antitumor immune activity. Tovecimig Tovecimig is a DLL4 and VEGF-A...

Recent company news

CMPXCompass Therapeutics2026-11-02 14:00 EST

Compass Therapeutics to Participate in Upcoming November Investor Events

CMPXCompass Therapeutics2026-10-24 08:15 EST

Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026

CMPXCompass Therapeutics2026-10-14 20:30 EST

Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CMPXCompass Therapeutics2026-09-22 12:30 EST

Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

Stock data

Close
0.68 USD
Market cap
374.58M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States